Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$18.59 USD
+0.10 (0.54%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.58 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RCKT 18.59 +0.10(0.54%)
Will RCKT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCKT
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Other News for RCKT
Rocket Pharmaceuticals files automatic mixed securities shelf
Rocket Pharmaceuticals (RCKT) Receives a Buy from Bank of America Securities
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Zymeworks (ZYME) and Rocket Pharmaceuticals (RCKT)
Solid Clinical Progress and Strong Financial Position Reinforce Buy Rating for Rocket Pharmaceuticals
Analysts Offer Insights on Healthcare Companies: American Well (AMWL), Rocket Pharmaceuticals (RCKT) and Relay Therapeutics (RLAY)